American journal of cancer research最新文献

{"title":"Development and validation of a machine learning-based model to predict postoperative overall survival in patients with soft tissue sarcoma: a retrospective cohort study.","authors":"Xu Liu, Jin Yuan, Xinfeng Wang, Shengji Yu","doi":"10.62347/ZQVY3877","DOIUrl":"10.62347/ZQVY3877","url":null,"abstract":"<p><strong>Background: </strong>The aim of this study is to develop a machine learning-based model to predict postoperative overall survival (OS) in patients with soft tissue sarcoma (STS) that demonstrates superior comprehensive performance.</p><p><strong>Methods: </strong>This analysis leveraged data from the SEER database spanning 2010-2020, alongside a STS cohort from the National Cancer Center. Machine learning methods were applied for predictor selection by wrapper methods and the development of the predictive model. The optimal model was determined using the concordance index (C-index), time-dependent calibration curves, time dependent receiver operating characteristic (ROC) curves, and decision curve analysis (DCA).</p><p><strong>Results: </strong>Six machine learning learners identified six feature subsets. Subsequently, six feature subsets and six machine learning learners were combined, resulting in the development of 36 prognostic models. The CAM model, exhibiting the highest prediction performance, was selected. The CAM model achieved a C-index of 0.849 (95% CI 0.837-0.859) in the training cohort and 0.837 (95% CI 0.809-0.871) in the validation cohort. Furthermore, time-dependent calibration curves, time-dependent ROC curves, and DCA indicate that the PAM demonstrates excellent calibration, predictive accuracy, and clinical net benefit. A publicly accessible web tool was developed for the CAM. Notably, CAM's performance exceeds that of all existing STS prognostic nomograms and prediction models.</p><p><strong>Conclusions: </strong>The CAM has the potential to identify postoperative OS in STS patients. This can assist clinicians in assessing the severity of the disease, facilitating patient follow-up, and aiding in the formulation of adjuvant treatment strategies.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"14 10","pages":"4731-4746"},"PeriodicalIF":3.6,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11560808/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142646202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The modified melphalan and busulfan-based regimen combined with maintenance therapy improved the survival of patients with refractory/relapsed AML after allogeneic transplantation: middle-term outcome of a multicenter trial.","authors":"Shulian Chen, Xiaoyu Zhang, Ting Niu, Yajing Xu, Guangxun Gao, Shengjin Fan, Zeping Zhou, Fang Zhou, Fei Li, Li Liu, Wei Yang, Qifa Liu, Xi Zhang, Yi He, Sizhou Feng, Mingzhe Han, Weihua Zhai, Erlie Jiang","doi":"10.62347/SKXB3242","DOIUrl":"10.62347/SKXB3242","url":null,"abstract":"<p><p>Allogeneic hematopoietic stem cell transplantation (allo-HSCT) maintains the only promising curative option for patients with refractory/relapsed (R/R) acute myeloid leukemia (AML). However, the long-term survival results are suboptimal. Optimization of the conditioning regimen aims to eradicate leukemia blasts and reduce early relapse. Here we reported of the preliminary result of the prospective multicenter single arm study to evaluate the efficacy and safety of a modified dual alkylator-conditioning regimen, MCBC (regimen including Melphalan, Cladribine, Busulfan and Cyclophosphamide) (ChiCTR Registration ID: ChiCTR2000029936). This trial enrolled 56 patients from July 2020 to January 2022. With a median follow-up of 854 days (range 48 to 1343), the 2-year overall survival (OS) and relapse-free survival (RFS) were 60.7 ± 6.5% (95% CI 47.5-73.9) and 57.1 ± 6.6% (95% CI 43.8-70.5), respectively, the estimated 3-year OS and RFS rates were 58.9 ± 6.6% (95% CI 45.6-72.2) and 55.4 ± 6.6% (95% CI 41.9-68.8), respectively. A total of 19 patients experienced relapse, the 2-year cumulative incidence relapse (CIR) rate was 34.2 ± 6.6% (95% CI 19.5-44.8), the estimated 3-year CIR rate was 36.3 ± 6.7% (95% CI 21.1-46.7). Six patients died of severe infection or graft-versus-host disease (GVHD). The non-relapse mortality (NRM) rate was 11.8 ± 4.5% (95% CI 2.4-19.1). Mucositis was the main reported regimen-related toxicity, and it was well controlled. Subgroup analyses illustrated that blasts count ≥ 20% before HSCT and the absence of maintenance treatment after HSCT were poor predictors. Our study confirmed the excellent anti-leukemia activity and acceptable toxicity of the MCBC conditioning regimen in R/R AML. Opportune maintenance treatment after HSCT led to significantly improved OS and RFS.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"14 10","pages":"4969-4978"},"PeriodicalIF":3.6,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11560827/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142646588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of high-risk tumor characteristics in patients with localized prostate cancer using conventional combined with diffusion-weighted MRI imaging parameters.","authors":"Min Wang, Jianrong Wen, Peijun Liu","doi":"10.62347/XADT5737","DOIUrl":"10.62347/XADT5737","url":null,"abstract":"<p><p>The objective of this study was to investigate the utility of conventional imaging combined with diffusion-weighted magnetic resonance imaging (MRI) in identifying high-risk tumor characteristics in patients with localized prostate cancer. A retrospective cohort study was conducted on 194 patients who underwent surgery for localized prostate cancer. Patients were categorized into low-risk and high-risk groups based on clinical criteria. Imaging data were obtained using a MRI system, and various imaging parameters were analyzed, including T1-weighted imaging (T1WI), T2-weighted imaging (T2WI) signal intensities, diffusion-weighted MRI parameters, and their correlations with clinical characteristics. Statistical methods such as logistic regression, and receiver operating characteristic (ROC) analysis were employed to assess the diagnostic performance of the imaging parameters and to construct joint prediction models. A verification set prediction model was established and compared. The comparison of demographic and clinical characteristics between the low and high-risk groups revealed significant differences in the prostate-specific antigen (PSA) level, Gleason score, Tumor Size and prostate volume (PV). Standard imaging parameters, T1WI and T2WI signal intensities, exhibited significant differences between the low and high-risk groups. Additionally, diffusion-weighted MRI parameters, including signal intensities at different b values, apparent diffusion coefficient (ADC), K^trans, and K_ep, were notably associated with high-risk tumor characteristics in localized prostate cancer. Logistic regression analysis identified both standard imaging and diffusion-weighted MRI parameters as independent predictors of high-risk tumor characteristics. Furthermore, the ROC analysis demonstrated the diagnostic potential of T2WI signal intensity, signal intensity at 800 s/mm², and ADC in identifying high-risk tumors. Joint prediction models combining standard imaging and diffusion-weighted MRI parameters showed high predictive accuracy for high-risk tumor characteristics in localized prostate cancer, with Area Under the Curve (AUC) values of 0.777 for standard imaging, 0.826 for diffusion-weighted MRI, and 0.892 for the combined model. The AUC value for the prediction model in validation set was 0.860. In conclusion, this study underscores the diagnostic potential of conventional imaging combined with diffusion-weighted MRI in identifying high-risk tumor characteristics in patients with localized prostate cancer. Both standard imaging and diffusion-weighted MRI parameters were identified as non-invasive biomarkers for risk assessment and prognosis. These findings have implications for precision treatment of localized prostate cancer, highlighting the potential integration of imaging-based risk assessment tools into clinical practice for tailored treatment strategies and improved patient outcomes.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"14 10","pages":"4909-4921"},"PeriodicalIF":3.6,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11560813/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142646330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis and differentiation of Kaposiform hemangioendothelioma based on ultrasound radiomics.","authors":"Chuang Li, Weihong Dong, Yawei Li","doi":"10.62347/AQSJ3784","DOIUrl":"10.62347/AQSJ3784","url":null,"abstract":"<p><p>Kaposiform hemangioendothelioma (KHE) is a rare neoplasm of the newborn, but has a very high mortality rate. In this study, we explore the application value of ultrasound radiomics in the differential diagnosis of KHE so as to provide reference for early diagnosis of KHE. We selected 194 cases of children with suspected KHE admitted to Henan Provincial People's Hospital from March 2016 to April 2024 for this retrospective analysis. All children completed ultrasound examinations in our hospital. After pathological biopsy, 132 cases were diagnosed with KHE. Taking pathological biopsy as the gold standard, the diagnostic rate of ultrasound examination was determined. Our results showed that ultrasound examination diagnosed 124 cases with KHE. Compared with pathological biopsy, the diagnostic sensitivity, specificity, and accuracy of ultrasound were 81.82, 77.42, and 80.41%, respectively (Kappa = 0.725). Most of the children had a single lesion, often involving the skin. The tumor was hard in texture and red or purple in color and did not fade when pressed. The two-dimensional sonogram showed a solid heterogeneous echo mass in the soft tissue. The lesion was generally large, irregular in shape, and unclear in boundaries, extending to the adipose layer and forming a \"tree root-like\" change. Microscopically, crossed spindle-shaped cell bundles could be seen, showing diffuse multinodular infiltrative growth. Children with the Kasabach-Merritt phenomenon (KMP) generally had larger lesions. Subsequently, the children with KHE were assigned to a training set and a validation set in a ratio of 7:3. High-throughput data acquisition of the regions of interest (ROIs) on the ultrasound images was carried out to construct a KEH prediction model based on ultrasound radiomics, and validation analysis was conducted. We found the diagnostic accuracy rate of ultrasound radiomics was 91.41%, the sensitivity was 77.44%, and the specificity was 97.21%, which were better than those of the conventional ultrasound. In conclusion, ultrasound radiomics analysis is highly effective in the diagnosis of KHE, which can contribute to the early diagnosis rate of KHE.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"14 10","pages":"4935-4945"},"PeriodicalIF":3.6,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11560810/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142646203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced MRI improves diagnosis and efficacy evaluation of early-stage hepatocellular carcinoma.","authors":"Ya-Yun Wang, Jing Zhang, Xiong Zhuang, Qiu-Yan Jin, Liang-Qing Liu","doi":"10.62347/WYNK6968","DOIUrl":"10.62347/WYNK6968","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the use of hepatocyte-specific contrast agent Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (EOB-MRI) in the diagnosis and efficacy evaluation of patients with early-stage hepatocellular carcinoma.</p><p><strong>Methods: </strong>A retrospective clinical study was conducted on 157 patients diagnosed with stage Ia-Ib liver cancer. Of these, 100 patients underwent preoperative EOB-MRI, while 57 patients underwent contrast-enhanced computerized tomography (CECT). The study compared the accuracy, sensitivity, and specificity of these two imaging modalities in diagnosing early-stage hepatocellular carcinoma. In the EOB-MRI group, 100 patients underwent radiofrequency ablation or interventional procedures, and imaging data were collected post-scan. The following arterial and hepatobiliary phase enhancement features were analyzed: length-diameter difference (LDD), signal intensity ratio of metastases to liver parenchyma (RatioM/L), relative signal intensity difference (RSID), normalized relative enhancement (NRE), contrast-to-noise ratio (CNR), and apparent diffusion coefficient (ADC) values. Based on treatment outcomes, patients were categorized into high and low response rate groups, and the imaging parameters between these two groups were compared. Univariate and multivariate analyses were performed to evaluate the significance of these parameters in predicting patient outcomes.</p><p><strong>Results: </strong>The accuracy of lesion detection by EOB-MRI was 97.4%, significantly higher than that of CECT (80.0%) (P < 0.05). The area under the curve (AUC) for the EOB-MRI group was 0.923 (95% CI: 0.784-1.000), with a sensitivity of 97.4% and a specificity of 83.3%. In comparison, the AUC for the CECT group was 0.712 (95% CI: 0.582-0.843), with a sensitivity of 77.2% and a specificity of 65.2%. The median response rate of patients with early-stage hepatocellular carcinoma to systemic therapy was 60% (range: 36%-81%). Using 60% as the cut-off value, patients were divided into a high response rate group (n = 53) and a low response rate group (n = 47). Univariate and multivariate logistic regression analyses of the EOB-MRI parameters in both groups identified ADC and NRE as independent predictors for assessing the treatment efficacy of early-stage hepatocellular carcinoma.</p><p><strong>Conclusion: </strong>EOB-MRI is effective for both the diagnosis and evaluation of treatment efficacy in early-stage hepatocellular carcinoma.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"14 10","pages":"4855-4867"},"PeriodicalIF":3.6,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11560834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142646253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of abiraterone combined with prednisone in castration-resistant prostate cancer and its impact on miR-221/222 expression.","authors":"Bingxin Yu, Xingsheng Zuo, Chenglong Zhao","doi":"10.62347/VFUC8316","DOIUrl":"10.62347/VFUC8316","url":null,"abstract":"<p><strong>Objective: </strong>To assess the therapeutic efficacy of abiraterone combined with prednisone in patients with castration-resistant prostate cancer (CRPC) and investigate its effects on miR-221/222 expression.</p><p><strong>Methods: </strong>A retrospective cohort of 43 CRPC patients from Henan Provincial People's Hospital, People's Hospital of Zhengzhou University was divided into two groups: the treated group (n=22, treated with abiraterone and prednisone) and the control group (n=21, treated with prednisone acetate alone). Expression of miR-221/222 was quantified in CRPC cell lines using quantitative fluorescence polymerase chain reaction.</p><p><strong>Results: </strong>The treated group demonstrated significantly higher rates of bone pain relief and prostate-specific antigen (PSA) response compared to the control group (P=0.032, P=0.022, respectively). Post-treatment, the treated group also showed increased Karnofsky Performance Status scores and reduced plasma testosterone levels relative to controls (P=0.021, P=0.016). There was no significant difference in the incidence of adverse reactions between the treated group (31.82%) and the control group (28.57%) (P=0.125).</p><p><strong>Conclusions: </strong>Abiraterone combined with prednisone effectively relieves bone pain and improves PSA response rates in CRPC patients, suggesting benefits in enhancing quality of life and reducing testosterone levels without increasing adverse reactions. This therapy appears to have a safety profile comparable to that of conventional treatments.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"14 10","pages":"4708-4716"},"PeriodicalIF":3.6,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11560831/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142646206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatic arterial infusion chemotherapy in combination with lenvatinib and durvalumab versus standard first-line treatment gemcitabine and cisplatin plus durvalumab in advanced intrahepatic cholangiocarcinoma.","authors":"Rongce Zhao, Jing Zhou, Xinhao Xiong, Qiaoxuan Wang, Chunxiao Liu, Wei Wei, Shaohua Li, Rongping Guo","doi":"10.62347/HVOF5644","DOIUrl":"10.62347/HVOF5644","url":null,"abstract":"<p><p>In patients with advanced intrahepatic cholangiocarcinoma (ICC), clinical outcomes remain unsatisfactory despite the recommended first-line treatment of gemcitabine with cisplatin and durvalumab (GCD). We recently reported that hepatic arterial infusion chemotherapy (HAIC) in combination with lenvatinib and durvalumab (HLD) exhibited promising antitumor activity and manageable adverse events in patients with unresectable ICC. Here, we aimed to compare HLD with GCD in patients with advanced ICC. This retrospective study included consecutive patients with advanced ICC administered HLD or GCD between January 2020 and March 2024. Safety and patient outcomes, including overall and progression-free survival and objective response rate, were compared between the two groups. The study cohort included 31 and 28 patients in the HLD and GCD groups, respectively. Compared to the GCD group, the HLD group experienced significantly better overall survival (median, 15.8 vs. 9.6 months; <i>P</i> = 0.033), longer progression-free survival (median, 10.3 vs. 4.1 months; <i>P</i> = 0.007), and a higher objective response rate (46.2% vs. 13.1%; <i>P</i> = 0.009). By subgroup analysis, patients with single tumor, intrahepatic tumors >5 cm, or unilobar tumors benefited more from HLD treatment. Additionally, the rates of any grade and grade 3-4 adverse events were not significantly different between the two groups (100% vs. 92.9%, <i>P</i> = 0.221; 32.3% vs. 42.9%, <i>P</i> = 0.401; respectively). In conclusion, HLD treatment was tolerable and associated with better survival benefits compared to the standard first-line GCD treatment in patients with advanced ICC, especially in those with single tumor, intrahepatic tumors >5 cm, and unilobar tumors.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"14 10","pages":"4922-4934"},"PeriodicalIF":3.6,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11560836/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142650547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cabozantinib inhibits tumor growth in mice with ovarian cancer.","authors":"Patrick J Stiff, Elizabeth Kertowidjojo, Ronald K Potkul, Swarnali Banerjee, Swati Mehrotra, William Small, M Sharon Stack, Maureen L Drakes","doi":"10.62347/ZSWV1767","DOIUrl":"10.62347/ZSWV1767","url":null,"abstract":"<p><p>Ovarian cancer is usually detected in the advanced stages. Existing treatments for high grade serous ovarian cancer (HGSOC) are not adequate and approximately fifty percent of patients succumb to this disease and die within five years after diagnosis. We conducted pre-clinical studies in a mouse model of ovarian cancer to evaluate disease outcome in response to treatment with the multi-kinase inhibitor cabozantinib. Cabozantinib is a receptor tyrosine kinase inhibitor with multiple targets including vascular endothelial growth factor receptor-2 (VEGFR-2), associated with immune suppression in ovarian cancer. Mice (C57BL/6) were injected with ID8-RFP ovarian tumor cells and treated with cabozantinib. Studies investigated ascites development, tumor burden and regulation of anti-tumor immunity with treatment. Mice treated with cabozantinib had significantly decreased solid tumor burden and decreased malignant ascites as compared to untreated controls. Improved outcome in cabozantinib treated mice was associated with a significantly higher percentage of CD69 early activated T cells, a higher percentage of granzyme B secreting CD8 T cells, the enhanced release of cytokines and chemokines known to recruit CD8 T cells and amplify T cell function, as well as reduced VEGFR-2. Findings suggest that cabozantinib is an important clinical agent capable of improving ovarian cancer in mice potentially in part by priming the autologous immune system to promote anti-tumor immunity.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"14 10","pages":"4788-4802"},"PeriodicalIF":3.6,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11560812/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142646244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunological biomarkers and predictive model for recurrence of esophageal squamous cell carcinoma after combined immunotherapy and neoadjuvant chemotherapy.","authors":"Ke Yang, Fangmiao Gao, Chenxuan Zhou, Sinan Cao, Shuaining Chai, Linwei Li","doi":"10.62347/ELRQ9964","DOIUrl":"10.62347/ELRQ9964","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the association between preoperative immunological biomarkers and risk of esophageal squamous cell carcinoma (ESCC) recurrence within 3 years after combined immunotherapy and neoadjuvant chemotherapy.</p><p><strong>Methods: </strong>This retrospective case-control study included 348 ESCC patients who received immunotherapy and neoadjuvant chemotherapy in Henan Provincial People's Hospital between 2021 and 2023. Patients were divided into a recurrence (n=197) group and a non-recurrence (n=151) group based on their recurrence within 3 years. Tumor-infiltrating lymphocytes, serum tumor-specific antibodies, immune checkpoint expression, and HLA expression were analyzed and compared between groups. Correlation and regression analyses evaluated associations between biomarkers and recurrence risk. Then, a joint prediction model was established.</p><p><strong>Results: </strong>The study revealed that CD8+ and Perforin+ cell percentages were significantly associated with a lower risk of recurrence (P<0.001), while EGFR, HER2, p53, PD-L1, CTLA-4, Tim-3, and LAG-3 were linked to an increased risk of recurrence (P<0.001). Lifestyle factors like salted food consumption, regular hot drink intake, gastric atrophy, and vitamin A deficiency also contributed to ESCC recurrence prediction (all P<0.05). A predictive model incorporating immune markers and risk factors for predicting ESCC recurrence within three years post-treatment demonstrated an AUC of 0.986.</p><p><strong>Conclusion: </strong>Immunological biomarkers, including tumor-infiltrating lymphocytes, serum tumor antibodies, immune checkpoint expression, and HLA expression are associated with ESCC recurrence risk within 3 years of combined immunotherapy and neoadjuvant chemotherapy. These biomarkers may help stratify patients and guide management decisions.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"14 10","pages":"4896-4908"},"PeriodicalIF":3.6,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11560828/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142646306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive analysis of ferroptosis-related genes indicates that TRIM46 is a novel biomarker and promotes the progression of ovarian cancer via modulating ferroptosis and Wnt signaling pathway.","authors":"Shuang Liu, Chunmei Xiao, Yue Rong, Mingbo Liu, Ke Yang, Jing Tang, Zhigang Wang","doi":"10.62347/ONUY8904","DOIUrl":"10.62347/ONUY8904","url":null,"abstract":"<p><p>Ovarian cancer (OC) is a common gynecological malignant tumor with poor prognosis. One form of controlled cell death that requires iron is ferroptosis. This study utilized TCGA data analysis to identify differentially expressed genes (DEGs) related to ferroptosis in OC, revealing 2,333 up-regulated and 4,073 down-regulated genes. Venn diagrams identified 64 up-regulated and 120 down-regulated ferroptosis-related DEGs (FR-DEGs), with 15 showing a significant correlation with overall patient survival. Further analyses explored the expression, mutations, and copy number variations of these 15 FR-DEGs across various cancer types, constructing interaction networks. Molecular subtypes in OC were classified using these 15 FR-DEGs, revealing two subtypes (C1 and C2). Survival analysis identified a risk model for the C1 group based on these genes. Experimental validation highlighted TRIM46 as a key gene, with knockdown inhibiting OC cell proliferation and migration. TRIM46 was also associated with changes in ferroptosis-related markers and demonstrated a close connection with the Wnt signaling pathway, validated through Western blot experiments. Overall, the study provided a comprehensive understanding of the role of DEGs related to ferroptosis in OC, offering valuable insights into disease mechanisms and potential therapeutic targets.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"14 10","pages":"4686-4707"},"PeriodicalIF":3.6,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11560837/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142646184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}